TNP

GEXVal Inc., founded in 2018 and based in Fujisawa, Japan, is dedicated to the research and development of drugs aimed at treating orphan and intractable diseases, particularly in the fields of psychiatry, neurology, and pulmonary arterial hypertension. The company focuses on creating innovative and cost-effective treatment options for patients suffering from rare and incurable conditions. Through its efforts, GEXVal seeks to provide support and solutions for patients and families affected by these challenging diseases.

al+ is a Personal Artificial Intelligence which reconstructs individual personalities on the cloud by analyzing life log data of individuals and their groups. Based on the analysis of individual personalities, unproductive parts of labour will be automated and alt’s operating efficiency will be maximized. al+ users can focus on more productive, creative and sophisticated work. Using this methodology, we sincerely hope to contribute to the solution of different kinds of social problems.

PharmaBio Corporation is a healthcare company specializing in the contract development and manufacturing of cellular and tissue-based products. Founded in 1978 and headquartered in Nagoya, Japan, with an administrative branch in Tokyo, the company focuses on developing cell-based investigational new drugs, as well as offering contract testing services, including microbial safety testing. PharmaBio operates a GMP-compliant cell storage facility for cell-based drugs and test specimens and provides genetic testing for pathogenic viruses and microbes. Additionally, the company offers strategic development consultation and research services to facilitate regulatory advancements in cell and tissue-based medicine. Its commitment to enhancing safety and quality is reflected in its support for GCTP-compliant manufacturing, aiming to minimize risk and cost for its clients.

Developer of a droplet cell sorter designed to decontaminate cells. The company offers a device that can be operated aseptically and can be used in the cell purification process of cell production to purify stem cells used for cell therapy, enabling healthcare providers to efficiently prepare stem cells for therapeutic purposes.

GEXVal Inc., founded in 2018 and based in Fujisawa, Japan, is dedicated to the research and development of drugs aimed at treating orphan and intractable diseases, particularly in the fields of psychiatry, neurology, and pulmonary arterial hypertension. The company focuses on creating innovative and cost-effective treatment options for patients suffering from rare and incurable conditions. Through its efforts, GEXVal seeks to provide support and solutions for patients and families affected by these challenging diseases.

PharmaBio Corporation is a healthcare company specializing in the contract development and manufacturing of cellular and tissue-based products. Founded in 1978 and headquartered in Nagoya, Japan, with an administrative branch in Tokyo, the company focuses on developing cell-based investigational new drugs, as well as offering contract testing services, including microbial safety testing. PharmaBio operates a GMP-compliant cell storage facility for cell-based drugs and test specimens and provides genetic testing for pathogenic viruses and microbes. Additionally, the company offers strategic development consultation and research services to facilitate regulatory advancements in cell and tissue-based medicine. Its commitment to enhancing safety and quality is reflected in its support for GCTP-compliant manufacturing, aiming to minimize risk and cost for its clients.

Normee Limited specializes in palm recognition technology that utilizes the built-in cameras of smartphones and tablets to identify users based on their unique palm patterns, including lines, ridges, veins, and capillaries. Founded on February 1, 2005, and headquartered in Tokyo, Japan, Normee's innovative system allows for accurate palm vein authentication using standard visible-spectrum cameras. This technology enables clients to adopt hybrid biometric authentication tailored to their specific operating environments, enhancing security and user experience. Normee was previously known as Universal Robot Co., Ltd.

CONNECTEC JAPAN Corporation develops semiconductor and electrical products. The company develops and provides foundry service of semiconductor package. It also provides technical support services for SMT, as well as various evaluation, analysis, and reliability test services. The company was founded in 2009 and is based in Myoko, Japan. It has a satellite in Kyoto, Japan, as well as sales offices in Seoul, Korea; and Suzhou, China.

i3Systems specializes in cloud and mobile solutions with a particular emphasis on enterprise mobile management services. The company offers a suite of business applications under the CLOMO brand, which includes tools such as CLOMO Browser, CLOMO Mailer, CLOMO Calendar, CLOMO Address Book, and CLOMO File Sharing. By leveraging advanced technology and engineering, i3Systems aims to enhance the operations of businesses, facilitating innovation and improving overall user experience. The company is committed to fostering a healthy work environment for its employees while ensuring that its services contribute positively to the lives of customers and their communities. Through its efforts, i3Systems envisions a future where technology is seamlessly integrated into daily life, bringing joy and value to all stakeholders involved.

SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, focused on the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in the fields of oncology and hematology. The company develops various anti-cancer agents, including Treakisym, which is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is currently undergoing Phase III trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is working on several other drug formulations, including SyB L-1701, SyB L-1702, and Rigosertib SyB-C-0501, as well as SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes. The company also has a candidate, SyB V-1901, aimed at treating infectious diseases. SymBio Pharmaceuticals operates primarily in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.

MiNO Wireless is a leading provider of managed alternative roaming services that enable mobile operators to capture revenue from budget conscious subscribers when they travel internationally. Through a seamless wireless network provided by MiNO's international mobile partnerships, mobile travelers have a local presence and enjoy a superior user experience that provides mobile voice, text and data coverage at very attractive rates.